• PTC Therapeutics posted Q2 total revenue of USD 361 million, more than doubled from a year earlier; net income swung to USD 83.5 million.
• Net product revenue more than doubled to USD 238.8 million, while royalty revenue rose to USD 71.1 million.
• Sephience revenue climbed 21% from Q1 to USD 151.3 million, with 1,647 patients on commercial therapy worldwide.
• Translarna revenue fell to USD 42.2 million; Emflaza dropped to USD 24.6 million due to continued generic erosion.
• 2026 total revenue outlook increased to USD 1.18 billion–USD 1.28 billion; product revenue guidance raised to USD 850 million–USD 950 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY16164) on July 30, 2026, and is solely responsible for the information contained therein.